MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction.
Shengjue XiaoTongneng XueQinyuan PanDefeng PanQi WuQiaozhi LiuXiaotong WangAilin LiuJie LiuDefeng PanYufei ZhouDefeng PanPublished in: Cardiovascular therapeutics (2021)
The incidence of MACEs in STEMI patients expressing high levels of miR-146a was significantly greater than in those expressing low levels. MicroRNA-146a can serve as a biomarker for adverse prognosis of STEMI and might function in its pathogenesis by targeting S100A12, which may exert its role via an inflammatory response. In addition, our study presents a valid and practical model to assess the probability of MACEs within three years of STEMI.
Keyphrases
- st segment elevation myocardial infarction
- percutaneous coronary intervention
- inflammatory response
- st elevation myocardial infarction
- end stage renal disease
- acute coronary syndrome
- coronary artery disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- long non coding rna
- atrial fibrillation
- immune response
- prognostic factors
- long noncoding rna
- lps induced
- patient reported outcomes